Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission-Reference-Cited by-同舟云学术

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Published:2020-12-24 Issue:26 Volume:383 Page:2526-2537
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Wei Andrew H.¹,Döhner Hartmut¹,Pocock Christopher¹,Montesinos Pau¹,Afanasyev Boris¹,Dombret Hervé¹,Ravandi Farhad¹,Sayar Hamid¹,Jang Jun-Ho¹,Porkka Kimmo¹,Selleslag Dominik¹,Sandhu Irwindeep¹,Turgut Mehmet¹,Giai Valentina¹,Ofran Yishai¹,Kizil Çakar Merih¹,Botelho de Sousa Aida¹,Rybka Justyna¹,Frairia Chiara¹,Borin Lorenza¹,Beltrami Germana¹,Čermák Jaroslav¹,Ossenkoppele Gert J.¹,La Torre Ignazia¹,Skikne Barry¹,Kumar Keshava¹,Dong Qian¹,Beach C.L.¹,Roboz Gail J.¹

Affiliation:

1. From the Department of Clinical Haematology, Alfred Hospital, and the Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia (A.H.W.); the Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany (H. Döhner); Kent and Canterbury Hospital, Canterbury, United Kingdom (C.P.); Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, and Hospital Universitari i Politècnic La Fe, Valencia — both in Spain (P.M.); Raisa Gorbacheva Memorial...

Funder

Bristol-Myers Squibb Company

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2004444

Cited by 255 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches;Cancers;2024-02-05

2. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome;Clinical Lymphoma Myeloma and Leukemia;2024-02

3. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study;Annals of Hematology;2024-01-26

4. 5-methylcytosine RNA modification regulators-based patterns and features of immune microenvironment in acute myeloid leukemia;Aging;2024-01-25

5. Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium;Cancers;2024-01-24